Clinical Trials Browser

Phase 2 × Meningioma × Nivolumab × Clear all

NCT02648997 2026-01-26

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

Phase 2 Active not recruiting

40 enrolled 14 charts

Meningioma

NCT03173950 2025-06-29

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Phase 2 Completed

Brain Neoplasms, Ependymoma, Medulloblastoma, Meningioma, Pinealoma, Spinal Cord Neoplasms, Choroid Plexus Neoplasms